In a new report, Oxfam concludes that Pfizer, Merck, Johnson & Johnson and Abbott dodge $3.7 billion annually—$2.3 billion in the U.S. alone—by shifting profits to tax havens, where subsidiaries pay a lower rate.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,